Karamvir Yadav, Medical Oncologist in Jaipur, India, shared a post on X:
“TACO Trial
Tri-weekly cisplatin (75 mg/m² q3w) vs weekly cisplatin (40 mg/m²) with concurrent RT in LACC.
Results:
- No difference in RFS or OS
- Similar recurrence patterns
- Lower hematologic toxicity with tri-weekly dosing
Clinical takeaway: Tri-weekly cisplatin is a valid alternative regimen.”
Title: A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study
Authors: S.Y. Ryu, B.H. Nam, M.H. Kim, W.I. Jang, C. Sitathanee, T.D. Linh, K.H. Lee, W.M. Lee, E.T. Kim, S.B. Kang, J.H. Kim, J.Y. Park, K.B. Lee, C.H. Cho, H. Lou, Y.H. Kim, Y.T. Kim, Y.H. Lee, X. Wu, J.W. Kim, S.I. Park, S. Jeon, D.H. Thinh, S.F. Kry, D. Gaffney, W. Small, S. Wilailak
Read the Full Article.
Other articles featuring Karamvir Yadav on OncoDaily.